Assessment of Secondary Hyperparathyroidism as a ‎Cause of Pulmonary Hypertension among End Stage ‎Renal Disease Patients on Regular Hemodialysis

Abstract

: Background: End-stage renal disease can result in several systemic consequences that pose a significant risk to life, such as cardiovascular disorders. Pulmonary arterial hypertension, characterized by increased blood pressure in the pulmonary artery, poses a significant risk for both morbidity and mortality in individuals with end-stage renal disease (ESRD). Aim‎ of‎ the‎ study: The aim of the current study was to evaluate association between hyperparathyroidism and incidence of pulmonary hypertension among haemodialysis patients. Methods:‎ This study was performed on 100 haemodialysis patients; they were divided according to incidence of pulmonary hypertension into 2 groups: 63 pulmonary hypertension patients and 37 patients without pulmonary hypertension. Results:‎ The most reported leading cause of end-stage renal disease was hypertension (65%), analgesic nephropathy (11%) and diabetic nephropathy (9%). About 27% of patients had residual urine output.The included patients received hemodialysis for about 3.06 ± 1.5 years with average ultrafiltration rate 3.3 ± 1.15 L. About 96% of patients received hemodialysis via A-v fistula and mean A-v fistula flow volume was 1111.7 ± 434.1. Conclusion: Disturbance in parathyroid release significantly affected incidence of pulmonary hypertension. Also, hypoparathyroidism is associated with increased incidence rate of pulmonary hypertension .